Monday, 24 Feb 2020

Biologic/Novel Rx

Date Typesort ascending Title Save
13 Mar 2017 Social Review of severe alopecia areata 90pts Rx w/ Xeljanz: 20% nearly total regrowth, 58% >50% regrowth,77% some regrowth https://t.co/8BZwOqevct
23 Oct 2015 Social Pretreatment CRP or IL-6 levels are not predictive of responses to tocilizumab https://t.co/IOQGWOGGQA
12 Nov 2019 Social RT @uptoTate: Drs. Davila and Solow say “No good data to suggest that biologic DMARDs contribute to progression of MGUS so okay to treat as…
17 Jun 2015 Social Metanalysis of 7 RCTs compares high vs low dose RTX in RA shows little clinical difference. Better Xray w/ high dose http://t.co/ySSo3gVKE8
07 Sep 2017 Social In 10yrs MTX/biologic use increased (40%/1.7% to 64%/27%) & rate of ortho surgery dropped (72 to 51/1000 pts in 2014 https://t.co/IE72n2YMPB
14 Apr 2017 Social How will new BIOSIMILAR biologic drugs affect PATIENTS - Make Your views count in a Patient survey; vote at>> https://t.co/ZhM9MiDCd7
21 Apr 2017 Social Small study of 13 alopecia pts (2 totalis, 7universalis); Xeljanz Rx 7/13 had >50% regrowth w/in 9 mos, 2 d/c https://t.co/w5OxVvdIvQ
30 Aug 2016 Social Dr Carol Langford Gr Rounds - ANCA levels do NOT correlate well with disease activity and should not be used to guide therapy
28 Dec 2017 Social This is the single best source on Biologics for Patients - Download the Patient Guide to Biologics from RheumNow. 6 pages of overview/comparisons; 5 biologic handouts https://t.co/D80f7I6Sr7
21 Nov 2019 Social FINCH3: FILGOTINIB studied in this cohort naive to MTX; interesting that safety data looks good! Maybe too early to tell. Abst# 927 https://t.co/AonswiGYG3 https://t.co/q3OU582WbT
28 Aug 2015 Social FDA issues guidance document- Nonproprietary Naming of Biological Products (includes biosimilars) http://t.co/lsLmHbQS0t
05 Nov 2017 Social RT @HealioRheum: Maternal #biologic use did not increase risk for opportunistic infections in #newborns https://t.co/1Iaj1awDK0 #ACR17 http…
20 Mar 2016 Social Tofacitinib meets primary endpoints in ulcerative colitis trials, achieving 16-18% remission rates https://t.co/mkWZTfz213
29 Mar 2018 Social Large BSRBR study of Serious infections w/ biologics shows SI=5.51 per 100PY for all; tocilizumab was higher vs ETN (HR 1.22; 1.02 to 1.47) & certolizumab lower or equal to ETN. 30-day mortality following SI was 10.4% (95% CI 9.2% to 11.6%). https://t.co/h5BieShHpH
08 Oct 2018 Social "Therapeutic Update: Biosimilars in Rheumatology" video series features nine experts talking about biosimilars, sponsored by Sandoz, Inc. Visit RheumNow to watch: https://t.co/1vmnEJqOSi #biosimilars https://t.co/WM1EINjFGy
17 Jan 2020 Social Analysis of worldwide data on Abatacept shows that compared with other bDMARDs, ABA was not associated with an increased overall cancer risk [ROR 0.98 (95% CI 0.91, 1.05)], but may be increased for risk of melanoma [1.58 (95% CI 1.17, 2.08)] https://t.co/3EI52M5kIR
31 Jan 2017 Social @jhoronjeff @pfizer @US_FDA You missed the point - this is the kind of study that must be done to get an interchangeability indication
29 Nov 2016 Social Good, basic overview of Biosimilars. https://t.co/N0hE8xL8Ga
06 May 2016 Social A FREE Patient Guide to Biologic Use - available now at the RheumNow Website. 13 pages jammed with Patient Education https://t.co/f4BJvLu84N
29 May 2018 Social RT @LCalabreseDO: Interesting study by a careful group of Irish investigators on new biologic approach to GCA- needs f/u!! Ustekinumab: N…